BPC-157
BPC-157 is a regenerative peptide renowned for its ability to accelerate healing and protect the body at the cellular level.
Originally derived from a naturally occurring gastric protein, this 15-amino-acid sequence has been studied for effects on tissue repair, gastrointestinal protection, and inflammation.
Overview
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a naturally occurring protein found in human gastric juice. Originally isolated from gastric secretions, BPC-157 represents the stable, active terminal fragment of the larger Body Protection Compound that contributes to gastric cytoprotection and mucosal integrity.
This peptide has gained considerable attention in regenerative medicine due to its demonstrated pleiotropic beneficial effects in preclinical models, particularly in tissue healing, vascular repair, and inflammatory modulation. BPC-157 exhibits remarkable stability in human gastric juice and maintains bioactivity across various physiological conditions, making it unique among therapeutic peptides.
.avif)
Chemical structure & Properties
- Molecular Formula: C62H98N16O22
- Molecular Weight: 1419 Da
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Half-life: Less than 30 minutes (hepatic metabolism)
- Stability: Resistant to gastric acid degradation, stable in human gastric juice
Mechanism of Action
BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways:
Areas Investigated in
the Research Literature
.avif)
Current Clinical Evidence
Primary Pathways: BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways.
Safety Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: Previously listed as Category 2. Nominated but withdrawn as of April 22, 2026
- Approval Status: Not approved for human therapeutic use
- Compounding: On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee recommended BPC-157 for inclusion on the 503A Bulks List. The recommendation is advisory and non-binding; final FDA rulemaking remains pending.
- Regulatory Position: Insufficient evidence for safety determination
WADA Status
- Classification: Prohibited under S0: Non-Approved Substances
- Athletic Use: Banned in competitive sports
- Testing: Detectable in anti-doping screenings
Legal Availability
- Commercial Status: Not legally available as prescription medication
- Market Presence: Sold through research-chemical suppliers.
- Quality Control: No regulatory oversight for purity or potency
- Clinical Use: Limited to research settings and experimental protocols
.avif)
Conclusion
What the evidence supports
BPC-157 has been studied in animal and cell-culture models of tendon, ligament and gastrointestinal healing, where reduced inflammation and accelerated tissue repair have been reported. Those results have not been carried into controlled human trials; the published human reports are small and uncontrolled, and there is no long-term human safety data. BPC-157 is not FDA approved for any therapeutic use; a July 2026 Pharmacy Compounding Advisory Committee recommendation to add it to the 503A bulk drug substances list is advisory and non-binding, and final FDA rulemaking remains pending. This page summarizes the published research and nothing further.
BPC-157 SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. BPC-157 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.